The action of the drug on the human body is called Pharmacodynamics in Medical terminology. To produce its effect and to change the pathological process that is happening the body and to reduce the symptom or cure the disease, the medicine has to function in a specific way. The changes it does to the body at cellular level gives the desired result of treating a disease. Drugs act by stimulating or inhibiting a receptor or an enzyme or a protein most of the times. Medications are produced in such a way that the ingredients target the specific site and bring about chemical changes in the body that can stop or reverse the chemical reaction which is causing the disease.
sponsored
Pharmacology:Calcimax-K2 is the active form of vitamin D3 (cholecalciferol). The natural or endogenous supply of vitamin D in man mainly depends on ultraviolet light for conversion of 7-dehydrocholesterol to vitamin D3 in the skin. Vitamin D3 must be metabolically activated in the liver and the kidney before it is fully active on its target tissues. The initial transformation is catalyzed by a vitamin D3-25-hydroxylase enzyme present in the liver, and the product of this reaction is 25-(OH)D3 (calcifediol). The latter undergoes hydroxylation in the mitochondria of kidney tissue and this reaction is activated by the renal 25-hydroxyvitamin D3-1-α-hydroxylase to produce 1,25-(OH)2D3(Calcimax-K2), the active form of vitamin D3.
The known sites of action of Calcimax-K2 are intestine, bone, kidney and parathyroid gland. Calcimax-K2 is the most active known form of vitamin D3 in stimulating intestinal calcium transport. In acutely uremic rats, Calcimax-K2 has been shown to stimulate intestinal calcium absorption. In bone, Calcimax-K2, in conjunction with parathyroid hormone (PTH), stimulates resorption of calcium; and in the kidney, Calcimax-K2 increases the tubular reabsorption of calcium. In vitro and in vivo studies have shown that Calcimax-K2 directly suppresses secretion and synthesis of PTH. A vitamin D-resistant state may exist in uremic patients because of the failure of the kidney to adequately convert precursors to the active compound, Calcimax-K2.
Calcimax-K2 when administered by bolus injection is rapidly available in the bloodstream. Vitamin D metabolites are known to be transported in blood, bound to specific plasma proteins. The pharmacologic activity of an administered dose of Calcimax-K2 is about 3-5 days. Two metabolic pathways for Calcimax-K2 have been identified, conversion to 1,24,25-(OH)3D3 and to calcitroic acid.
Toxicology:Preclinical Safety Data: Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Calcimax-K2. There was no evidence of mutagenicity as studied by the Ames method. No significant effects of Calcimax-K2 on fertility were reported using oral Calcimax-K2.
How should I take Calcimax-K2?
It is very important that you use Calcimax-K2 only as directed by your doctor. Do not use more of it, do not use it more often, and do not use it for a longer time than your doctor ordered. To do so may cause unwanted side effects or skin irritation.
Calcimax-K2 should only be used on the skin. Do not get it into your eyes, nose, mouth, or vagina. Do not use it on skin areas that have cuts, scrapes, or burns. Do not apply Calcimax-K2 to your nipple or areola, if you are breastfeeding. If it does get on these areas, rinse it off right away with water.
Calcimax-K2 comes with a patient information leaflet. Read and follow the instructions carefully. Ask your doctor if you have any questions.
To use the ointment:
Wash your hands with soap and water before and after using Calcimax-K2. If the skin on your hands is being treated with the medicine, only wash the skin that is not affected.
Apply a thin layer to the affected area of the skin. Rub it in gently until it disappears into the skin.
Do not get any medicine into your eyes, lips, or face.
Do not cover the treated skin area unless your doctor told you to.
Do not use cosmetics or other skin care products on the treated areas unless directed to do so by your doctor.
Dosing
The dose of Calcimax-K2 will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of Calcimax-K2. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
For topical dosage form (ointment):
For plaque psoriasis:
Adults and children 7 years of age and older—Apply to the affected area of the skin 2 times a day in the morning and evening. Do not use more than 200 grams (g) per week.
Children 2 to 6 years of age—Apply to the affected area of the skin 2 times a day in the morning and evening. Do not use more than 100 g per week.
Children younger than 2 years of age—Use and dose must be determined by your doctor.
Missed dose
If you miss a dose of Calcimax-K2, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.
Storage
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Do not freeze or refrigerate the ointment.
Calcimax-K2 administration
Administration of drug is important to know because the drug absorption and action varies depending on the route and time of administration of the drug. A medicine is prescribed before meals or after meals or along with meals. The specific timing of the drug intake about food is to increase its absorption and thus its efficacy. Few work well when taken in empty stomach and few medications need to be taken 1 or 2 hrs after the meal. A drug can be in the form of a tablet, a capsule which is the oral route of administration and the same can be in IV form which is used in specific cases. Other forms of drug administration can be a suppository in anal route or an inhalation route.
sponsored
Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Calcimax-K2 topical is usually applied once in the morning and once in the evening. Follow your doctor's instructions.
Do not share this medication with other people, even if they have the same symptoms you have.
Wash your hands before and after applying this medicine.
Apply a thin layer of the medication and rub it in completely.
Do not cover treated skin areas unless your doctor has told you to.
Calcimax-K2 topical is for use only on areas of psoriasis. Avoid getting it on healthy skin areas.
Calcimax-K2 topical should not be applied to the face or the vaginal area.
Store at room temperature away from moisture and heat. Do not allow the medicine to freeze.
Calcimax-K2 pharmacology
Pharmacokinetics of a drug can be defined as what body does to the drug after it is taken. The therapeutic result of the medicine depends upon the Pharmacokinetics of the drug. It deals with the time taken for the drug to be absorbed, metabolized, the process and chemical reactions involved in metabolism and about the excretion of the drug. All these factors are essential to deciding on the efficacy of the drug. Based on these pharmacokinetic principles, the ingredients, the Pharmaceutical company decides dose and route of administration. The concentration of the drug at the site of action which is proportional to therapeutic result inside the body depends on various pharmacokinetic reactions that occur in the body.
Calcimax-K2 is the active form of vitamin D3 (cholecalciferol). The natural or endogenous supply of vitamin D in man mainly depends on ultraviolet light for conversion of 7-dehydrocholesterol to vitamin D3 in the skin. Vitamin D3 must be metabolically activated in the liver and the kidney before it is fully active on its target tissues. The initial transformation is catalyzed by a vitamin D3-25-hydroxylase enzyme present in the liver, and the product of this reaction is 25-(OH)D3 (calcifediol). The latter undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-α-hydroxylase to produce 1,25-(OH)2D3 (Calcimax-K2), the active form of vitamin D3.
The known sites of action of Calcimax-K2 are intestine, bone, kidney and parathyroid gland. Calcimax-K2 is the most active known form of vitamin D3 in stimulating intestinal calcium transport. In acutely uremic rats, Calcimax-K2 has been shown to stimulate intestinal calcium absorption. In bone, Calcimax-K2, in conjunction with parathyroid hormone, stimulates resorption of calcium; and in the kidney, Calcimax-K2 increases the tubular reabsorption of calcium. In vitro and in vivo studies have shown that Calcimax-K2 directly suppresses secretion and synthesis of PTH. A vitamin D-resistant state may exist in uremic patients because of the failure of the kidney to adequately convert precursors to the active compound, Calcimax-K2.
Calcimax-K2 when administered by bolus injection is rapidly available in the blood stream. Vitamin D metabolites are known to be transported in blood, bound to specific plasma proteins. The pharmacologic activity of an administered dose of Calcimax-K2 is about 3 to 5 days. Two metabolic pathways for Calcimax-K2 have been identified, conversion to 1,24,25-(OH)3D3 and to calcitroic acid.
sponsored
References
DailyMed. "CALCITRIOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
NCIt. "Calcitriol: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
EPA DSStox. "Calcitriol: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/ds... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Calcimax-K2 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Calcimax-K2. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
2 consumers reported administration
When best can I take Calcimax-K2, on an empty stomach, before or after food? ndrugs.com website users have also released a report stating that Calcimax-K2 should be taken After food. In any case, this may not be the right description on how you ought to take this Calcimax-K2. Kindly visit your doctor for more medical advice in this regard. Click here to see other users view on when best the Calcimax-K2 can be taken.
Users
%
After food
2
100.0%
Consumer reviews
There are no reviews yet. Be the first to write one!
